User menu

Moxifloxacin safety: An analysis of 14 years of clinical data

Bibliographic reference Tulkens, Paul M. ; Arvis, Pierre ; Kruesmann, Frank. Moxifloxacin safety: An analysis of 14 years of clinical data. In: Drugs in R & D, Vol. 12, no. 2, p. 71-100 (2012)
Permanent URL
  1. Woodhead M., Blasi F., Ewig S., Garau J., Huchon G., Ieven M., Ortqvist A., Schaberg T., Torres A., van der Heijden G., Read R., Verheij T.J.M., Guidelines for the management of adult lower respiratory tract infections - Full version, 10.1111/j.1469-0691.2011.03672.x
  2. Mandell Lionel A., Wunderink Richard G., Anzueto Antonio, Bartlett John G., Campbell G. Douglas, Dean Nathan C., Dowell Scott F., File Thomas M., Musher Daniel M., Niederman Michael S., Torres Antonio, Whitney Cynthia G., Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults, 10.1086/511159
  3. Balter Meyer S, La Forge Jacques, Low Donald E, Mandell Lionel, Grossman Ronald F, the Chronic Bronchitis Working Group, Canadian Guidelines for the Management of Acute Exacerbations of Chronic Bronchitis, 10.1155/2003/486285
  4. Solomkin Joseph S., Mazuski John E., Bradley John S., Rodvold Keith A., Goldstein Ellie J. C., Baron Ellen J., O’Neill Patrick J., Chow Anthony W., Dellinger E. Patchen, Eachempati Soumitra R., Gorbach Sherwood, Hilfiker Mary, May Addison K., Nathens Avery B., Sawyer Robert G., Bartlett John G., Diagnosis and Management of Complicated Intra‐abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America, 10.1086/649554
  5. Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130 (1 Suppl.): 1–45.
  6. Sociedad Española de Quimioterapia, Sociedad Española de Otorrinolaringología y Patología Cérvico-Facial. Diagnosis and antimicrobial treatment of sinusitis. Rev Esp Quimioter 2003; 16 (2): 239–51.
  7. Clinical Effectiveness Group, British Association for Sexual Health and HIV. UK national guideline for the management of pelvic inflammatory disease 2011 (updated June 2011) [online]. Available from URL: [Accessed 2012 Jan 28].
  8. Stevens Dennis L., Bisno Alan L., Chambers Henry F., Everett E. Dale, Dellinger Patchen, Goldstein Ellie J. C., Gorbach Sherwood L., Hirschmann Jan V., Kaplan Edward L., Montoya Jose G., Wade James C., Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections, 10.1086/497143
  9. Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 Suppl. 1: 13–17.
  10. Pham PA, Bartlett JG. Moxifloxacin [online]. Available from [Accessed 2012 Jan 28].
  11. Barman Balfour Julia A., Wiseman Lynda R., Moxifloxacin : , 10.2165/00003495-199957030-00007
  12. Krasemann C., Meyer J., Tillotson G., Evaluation of the Clinical Microbiology Profile of Moxifloxacin, 10.1086/319377
  13. Culley CM, Lacy MK, Klutman N, et al. Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm 2001; 58 (5): 379–88.
  14. Talan David A., Clinical Perspectives on New Antimicrobials: Focus on Fluoroquinolones, 10.1086/319378
  15. Zhanel George G., Ennis Kelly, Vercaigne Lavern, Walkty Andrew, Gin Alfred S., Embil John, Smith Heather, Hoban Daryl J., A Critical Review of the Fluoroquinolones : Focus on Respiratory Infections, 10.2165/00003495-200262010-00002
  16. Blondeau Joseph M., The Role of Fluoroquinolones in Skin and Skin Structure Infections : , 10.2165/00128071-200203010-00004
  17. Muijsers Richard B.R., Jarvis Blair, Moxifloxacin : In Uncomplicated Skin and Skin Structure Infections, 10.2165/00003495-200262060-00008
  18. Ball Peter, Stahlmann Ralf, Kubin Rolf, Choudhri Shurjeel, Owens Robert, Safety profile of oral and intravenous moxifloxacin: Cumulative data from clinical trials and postmarketing studies, 10.1016/s0149-2918(04)90170-1
  19. Keating Gillian M, Scott Lesley J, Moxifloxacin : A Review of its Use in the Management of Bacterial Infections, 10.2165/00003495-200464200-00006
  20. Llor C., Naberan K., Cots J.M., Molina J., Miravitlles M., Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care, 10.1111/j.1368-5031.2004.00293.x
  21. Van Bambeke F., Michot J.-M., Van Eldere J., Tulkens P.M., Quinolones in 2005: an update, 10.1111/j.1469-0691.2005.01131.x
  22. Sethi Sanjay, Moxifloxacin for the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease, 10.1086/428058
  23. Grossman Ronald F., Rotschafer John C., Tan James S., Antimicrobial treatment of lower respiratory tract infections in the hospital setting, 10.1016/j.amjmed.2005.05.011
  24. Ferrara A. M., New Fluoroquinolones in Lower Respiratory Tract Infections and Emerging Patterns of Pneumococcal Resistance, 10.1007/s15010-005-4102-8
  25. Haggerty C. L., Ness R. B., Newest Approaches to Treatment of Pelvic Inflammatory Disease: A Review of Recent Randomized Clinical Trials, 10.1086/512191
  26. Miravitlles M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis 2007; 2 (3): 191–204.
  27. Miravitlles Marc, Anzueto Antonio, Moxifloxacin: a respiratory fluoroquinolone, 10.1517/14656566.9.10.1755
  28. Simoens Steven, Decramer Marc, A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin, 10.1517/14656566.9.10.1735
  29. Burkhardt Olaf, Welte Tobias, 10 years’ experience with the pneumococcal quinolone moxifloxacin, 10.1586/eri.09.46
  30. Simoens Steven, Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines, 10.1185/03007990903223663
  31. Sprandel Kelly A., Rocivold Keith A., Safety and tolerability of fluoroquinolones, 10.1016/s1098-3597(03)90027-5
  32. Iannini PB. Fluoroquinolone toxicity: a review of class- and agent-specific adverse effects. Drug Benefit Trends 2004; 16 Suppl. B: 34–41.
  33. Andriole Vincent T, Haverstock Daniel C, Choudhri Shurjeel H, Retrospective Analysis of the Safety Profile of Oral Moxifloxacin in Elderly Patients Enrolled in Clinical Trials : , 10.2165/00002018-200528050-00007
  34. Choudri SH, Kuesmann K, Perroncel R. Cardiac safety of moxifloxacin in hospitalized patients with community-acquired pneumonia [abstract no. L-1079]. 46th Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 Sep 27–30; San Francisco (CA).
  35. Van Bambeke Françoise, Tulkens Paul M., Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin : Comparison with Other Fluoroquinolones and Other Antibacterial Classes, 10.2165/00002018-200932050-00001
  36. Iannini Paul B, Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval, 10.1517/14740338.1.2.121
  37. Iannini Paul B., The safety profile of moxifloxacin and other fluoroquinolones in special patient populations, 10.1185/030079907x188099
  38. Stahlmann Ralf, Lode Hartmut, Fluoroquinolones in the Elderly : Safety Considerations, 10.2165/00002512-200320040-00005
  39. Stahlmann Ralf, Lode Hartmut, Safety Considerations of Fluoroquinolones in the Elderly : An Update, 10.2165/11531490-000000000-00000
  40. Grange JD, Thabut D, Lucidarme D, et al. Randomized, comparative study of moxifloxacin versus amoxicillin-clavulanate in the treatment of bacterial infections in cirrhotic patients [abstract no. 1086]. Hepatology 2004; 40 Suppl. S4:631A.
  41. Avelox®: US prescribing information [online]. Available from URL: [Accessed 2012 Jan 28].
  42. Avelox® 400 mg/250 mL solution pour perfusion: résumé des caractéristiques du produit [online]. Available from URL: [Accessed 2012 Jan 28].
  43. Avelox® 400 mg comprimés: résumé des caractéristiques du produit [online]. Available from URL: [Accessed 2012 Jan 28].
  44. Landen H, Möller M, Tillotson GS, Kubin R, Höffken G, Clinical Experience in Germany of Treating Community-Acquired Respiratory Infections with the New 8-Methoxyfluoroquinolone, Moxifloxacin, 10.1177/147323000102900202
  45. Barth J., Landen H., Efficacy and Tolerability of Moxifloxacin in 2338 Patients with Acute Exacerbation of Chronic Bronchitis : , 10.2165/00044011-200323010-00001
  46. Faich Gerald A, Morganroth Joel, Whitehouse Alan B, Brar Jugroop S, Arcuri Peter, Kowalsky Steven F, Haverstock Daniel C, Celesk Roger A, Church Deborah A, Clinical Experience with Moxifloxacin in Patients with Respiratory Tract Infections, 10.1345/aph.1c066
  47. Elies W, Landen H, Stauch K, Efficacy and Tolerability of Moxifloxacin in Patients with Sinusitis Treated in General Practice : Results of a Post-Marketing Surveillance Study, 10.2165/00044011-200424080-00001
  48. Koch H, Landen H, Stauch K, Daily-Practice Treatment of Acute Exacerbations of Chronic Bronchitis with Moxifloxacin in a Large Cohort in Germany : , 10.2165/00044011-200424080-00003
  49. Koch H, Landen H, Stauch K, Once-Daily Moxifloxacin Therapy for???Community-Acquired Pneumonia in???General Practice : Evidence from a Post-Marketing Surveillance Study of 1467 Patients, 10.2165/00044011-200424080-00002
  50. Barth J, Stauch K, Landen H, Efficacy and Tolerability of Sequential Intravenous/Oral Moxifloxacin Therapy in Pneumonia : Results of the First Post-Marketing Surveillance Study with Intravenous Moxifloxacin in Hospital Practice, 10.2165/00044011-200525110-00002
  51. Schaberg T, M??ller M, File T, Stauch K, Landen H, Real-Life Treatment of Acute Exacerbations of Chronic Bronchitis with Moxifloxacin or Macrolides : A Comparative Post-Marketing Surveillance Study in General Practice, 10.2165/00044011-200626120-00007
  52. Liu L. Y., Landen H., Treatment of respiratory tract infections with moxifloxacin: results of postmarketing surveillance in China : Treatment of respiratory tract infections with moxifloxacin, 10.1111/j.1742-1241.2007.01484.x
  53. Zhou Bing, Jiang Xuejun, Zhai Lijie, Xiao Shuifang, Wang Jiadong, Xiao Gensheng, Ruan Biao, Liang Chuanyu, Ye Qing, Hu Baohua, Wang Haibo, Moxifloxacin in the treatment of acute bacterial rhinosinusitis: Results of a multicenter, non-interventional study, 10.3109/00016481003629036
  54. Norrby S. Ragnar, Lietman Paul S., Safety and Tolerability of Fluoroquinolones : , 10.2165/00003495-199300453-00012
  55. Ball Peter, Tillotson Glenn, Tolerability of Fluoroquinolone Antibiotics Past, Present and Future : , 10.2165/00002018-199513060-00004
  56. Bertino Joseph, Fish Douglas, The safety profile of the fluoroquinolones, 10.1016/s0149-2918(00)80053-3
  57. Ball P., Adverse drug reactions: implications for the development of fluoroquinolones, 10.1093/jac/dkg209
  58. Juurlink D. N., Park-Wyllie L. Y., Kapral M. K., The effect of publication on Internet-based solicitation of personal-injury litigants, 10.1503/cmaj.070652
  59. European Medicines Agency. Withdrawal assessment report for garenoxacin mesylate (Garenoxacin): EMEA/H/C/747 [online]. Available from [Accessed 2011 Dec 13].
  60. European Medicines Agency. Withdrawal assessment report for Factive. International nonproprietary name: gemifloxacin. Procedure no. EMEA/H/C/995 [online]. Available from URL: [Accessed 2011 Dec 13].
  61. Bayer Schering Pharma-Bayer plc. Direct healthcare professional communication regarding moxifloxacin (Avelox®) and serious hepatic and bullous skin reactions [online]. Available from URL: [Accessed 2012 Jan 28].
  62. European Medicines Agency. Moxifloxacin [online]. Available from URL: [Accessed 2012 Jan 28].
  63. Council for International Organizations of Medical Sciences Working Group. Introductory guide for Standardised MedDRA Queries (SMQs) Version 13.0. Chantilly (VA): MedDRA Maintenance and Support Services Organization, 2010.
  64. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline. Statistical principles for clinical trials: E9 [online]. Available from URL: [Accessed 2012 Jan 28].
  65. Greenland Sander, Robins James M., Estimation of a Common Effect Parameter from Sparse Follow-Up Data, 10.2307/2530643
  66. Miravitlles Marc, Moxifloxacin in respiratory tract infections, 10.1517/14656566.6.2.283
  67. Craig WA. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. Am J Med 2004; 117 Suppl. 3A: 16S–22S.
  68. File Thomas M., Garau Javier, Jacobs Michael R., Wynne Brian, Twynholm Monique, Berkowitz Elchonon, Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains, 10.1016/j.ijantimicag.2004.10.007
  69. Aspa Javier, Rajas Olga, de Castro Felipe Rodríguez, Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia, 10.1517/14656566.9.2.229
  70. Croom Katherine F, Goa Karen L, Levofloxacin : A Review of its Use in the Treatment of Bacterial Infections in the United States, 10.2165/00003495-200363240-00008
  71. Klugman K.P., Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections, 10.1183/09031936.02.00400402
  72. Odenholt I., Cars O., Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model, 10.1093/jac/dkl356
  73. Lister Philip, Pharmacodynamics of Levofloxacin Against Characterized Ciprofloxacin-Resistant Streptococcus pneumoniae, 10.3810/pgm.2008.09.suppl52.284
  74. Brinker A. Telithromycin-associated hepatotoxicity [online]. Available from [Accessed 2012 Jan 28].